Trial · NCT01824875
Adverse events92
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 92
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Arm A (Temozolomide) | 21 | 68 | |
| other | Anemia | Blood and lymphatic system disorders | Arm B (Temozolomide and Capecitabine) | 27 | 71 | |
| other | Fatigue | General disorders | Arm A (Temozolomide) | 44 | 68 | |
| other | Fatigue | General disorders | Arm B (Temozolomide and Capecitabine) | 45 | 71 | |
| other | Palmar-plantar erythrodysesthesia syndrome | Skin and subcutaneous tissue disorders | Arm A (Temozolomide) | 3 | 68 | |
| other | Palmar-plantar erythrodysesthesia syndrome | Skin and subcutaneous tissue disorders | Arm B (Temozolomide and Capecitabine) | 23 | 71 | |
| other | Skin hyperpigmentation | Skin and subcutaneous tissue disorders | Arm A (Temozolomide) | 1 | 68 | |
| other | Skin hyperpigmentation | Skin and subcutaneous tissue disorders | Arm B (Temozolomide and Capecitabine) | 12 | 71 | |
| other | Abdominal pain | Gastrointestinal disorders | Arm A (Temozolomide) | 12 | 68 | |
| other | Abdominal pain | Gastrointestinal disorders | Arm B (Temozolomide and Capecitabine) | 13 | 71 | |
| other | Constipation | Gastrointestinal disorders | Arm A (Temozolomide) | 22 | 68 | |
| other | Constipation | Gastrointestinal disorders | Arm B (Temozolomide and Capecitabine) | 34 | 71 | |
| other | Diarrhea | Gastrointestinal disorders | Arm A (Temozolomide) | 16 | 68 | |
| other | Diarrhea | Gastrointestinal disorders | Arm B (Temozolomide and Capecitabine) | 30 | 71 | |
| other | Mucositis oral | Gastrointestinal disorders | Arm A (Temozolomide) | 6 | 68 | |
| other | Mucositis oral | Gastrointestinal disorders | Arm B (Temozolomide and Capecitabine) | 7 | 71 | |
| other | Nausea | Gastrointestinal disorders | Arm A (Temozolomide) | 41 | 68 | |
| other | Nausea | Gastrointestinal disorders | Arm B (Temozolomide and Capecitabine) | 51 | 71 | |
| other | Vomiting | Gastrointestinal disorders | Arm A (Temozolomide) | 20 | 68 | |
| other | Vomiting | Gastrointestinal disorders | Arm B (Temozolomide and Capecitabine) | 28 | 71 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01824875/events